Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer

Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer

Next-generation sequencing (NGS) is the technology of choice for the routine screening of tumor samples in clinical practice. In this setting, the targeted sequencing of a restricted number of clinically relevant genes represents the most practical option when looking for genetic variants associated...

Full description

Bibliographic Details
Main Authors:	Martina Dameri, Lorenzo Ferrando, Gabriella Cirmena, Claudio Vernieri, Giancarlo Pruneri, Alberto Ballestrero, Gabriele Zoppoli
Format:	Article
Language:	English
Published:	MDPI AG 2021-07-01
Series:	International Journal of Molecular Sciences
Subjects:	next-generation sequencing multi-gene testing gene panels breast cancer metastatic triple-negative breast cancer tumor mutational burden
Online Access:	https://www.mdpi.com/1422-0067/22/13/7154

Similar Items

Response to cisplatin in a metastatic triple-negative breast cancer patient
by: Budhi Singh Yadav, et al.
Published: (2021-01-01)

Combination of Ixabepilone and Capecitabine in Metastatic Triple Negative Breast Cancer. Clinical case
by: E. V. Glazkova, et al.
Published: (2019-12-01)

Systemic Therapy for Metastatic Triple Negative Breast Cancer: Current Treatments and Future Directions
by: Laura Morrison, et al.
Published: (2023-07-01)

Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial
by: Shuo Wu, et al.
Published: (2020-05-01)

Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach
by: Hana Kim, et al.
Published: (2021-11-01)

NGS Panel Testing of Triple-Negative Breast Cancer Patients in Cyprus: A Study of <i>BRCA</i>-Negative Cases
by: Maria Zanti, et al.
Published: (2020-10-01)

Development of cytotoxic chemotherapy in metastatic breast cancer with a triple-negative phenotype
by: E V Karabina, et al.
Published: (2016-06-01)

Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type
by: Md Abdus Subhan, et al.
Published: (2023-04-01)

Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria
by: Juliane Hoyer, et al.
Published: (2018-09-01)

Metastatic Triple Negative Breast Cancer: The New Era of Thinking
by: Mohammed Amrallah A., et al.
Published: (2021-05-01)

In silico analysis of differentially expressed genesets in metastatic breast cancer identifies potential prognostic biomarkers
by: Jongchan Kim
Published: (2021-06-01)

Dynamic analysis of circulating tumor DNA to predict the prognosis and monitor the treatment response of patients with metastatic triple-negative breast cancer: A prospective study
by: Yajing Chi, et al.
Published: (2023-11-01)

Study of the Genetic Variants in <i>BRCA1/2</i> and Non-<i>BRCA</i> Genes in a Population-Based Cohort of 2155 Breast/Ovary Cancer Patients, Including 443 Triple-Negative Breast Cancer Patients, in Argentina
by: Angela R. Solano, et al.
Published: (2021-05-01)

Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality
by: Borker Rohit, et al.
Published: (2011-06-01)

Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting
by: Sarah S. Mougalian, et al.
Published: (2018-09-01)

Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacists’ Perspective
by: Shuanghe Li, et al.
Published: (2022-10-01)

Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer
by: Alberto Montero, et al.
Published: (2012-12-01)

Study on tumour suppressor gene TP53 mutation and prognosis in patients with triple-negative breast cancer
by: YANG Cuiyan, WANG Haoyu, CHEN Xiaosong, SHEN Kunwei
Published: (2022-09-01)

Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer
by: Jun Cao, et al.
Published: (2022-08-01)

The Association of Immune Cell Infiltration with Metastasis Location in De Novo Metastatic Triple Negative Breast Cancer: A Multicenter Cross-Sectional Study in Indonesia
by: Jeffry Beta Tenggara, et al.
Published: (2023-10-01)

Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center
by: Salah Mabrouk Khallaf, et al.
Published: (2020-04-01)

Targeting Cell Death Mechanism Specifically in Triple Negative Breast Cancer Cell Lines
by: Lavinia-Lorena Pruteanu, et al.
Published: (2022-04-01)

Association of Pathway Mutations With Survival in Taiwanese Breast Cancers
by: Po-Sheng Yang, et al.
Published: (2022-07-01)

A risk stratification model for predicting brain metastasis and brain screening benefit in patients with metastatic triple‐negative breast cancer
by: Mingxi Lin, et al.
Published: (2020-11-01)

Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review
by: Claire H. Li, et al.
Published: (2019-12-01)

Update on Classic and Novel Approaches in Metastatic Triple-Negative Breast Cancer Treatment: A Comprehensive Review
by: Salvatore Greco, et al.
Published: (2023-06-01)

A clinicopathologic study of triple negative breast cancer
by: Vandana L Gaopande, et al.
Published: (2015-01-01)

Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls
by: Sara Bravaccini, et al.
Published: (2021-11-01)

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
by: Giacomo Barchiesi, et al.
Published: (2021-11-01)

CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer
by: Lubaid Saleh, et al.
Published: (2021-12-01)

A Case Series Exploration of Multi-Regional Expression Heterogeneity in Triple-Negative Breast Cancer Patients
by: Qi Xu, et al.
Published: (2022-11-01)

A Real-World Multicentre Retrospective Study of Low-Dose Apatinib for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
by: Tianyu Zeng, et al.
Published: (2022-08-01)

Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities
by: Rita Ribeiro, et al.
Published: (2022-08-01)

PARP inhibitors in the treatment of metastatic breast cancer patients with germline BRCA1/2 mutations. Experience of treatment with talazoparib in clinical practice
by: M. A. Frolova, et al.
Published: (2020-07-01)

Triple-Negative Breast Cancer: One Or More Entities?
by: Matikas Alexios, et al.
Published: (2014-12-01)

Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice
by: Joyce O’Shaughnessy, et al.
Published: (2021-07-01)

Outcomes of non-metastatic triple negative breast cancers: Real-world data from a large Indian cohort
by: Jyoti Bajpai, et al.
Published: (2022-06-01)

Triple Negative Breast Cancer Profile, from Gene to microRNA, in Relation to Ethnicity
by: Ishita Gupta, et al.
Published: (2019-03-01)

Anti-metastatic and anti-proliferative activity of eugenol against triple negative and HER2 positive breast cancer cells
by: Mashan L. Abdullah, et al.
Published: (2018-12-01)

First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial
by: Liu MC, et al.
Published: (2019-12-01)